



**THE FOUNDATION  
FOR SECURE  
MARKETS®**

#58437

**Date:** February 27, 2026

**Subject:** Avidity Biosciences, Inc. – Further Adjustment  
Adjusted Option Symbol: RNA1  
Date: 02/27/2026  
\* \* \* Update \* \* \*

On February 23, 2026, Avidity Biosciences, Inc. (“RNA” which changed to “RNAS” on February 26, 2026) adjourned its special meeting to February 26, 2026, per the Supplement to the Proxy Statement for the Special Meeting filed February 23, 2026 (“Supplement”). At the special meeting, shareholders voted concerning i) the Agreement and Plan of Merger with Ajax Acquisition Sub, Inc., a wholly owned subsidiary of Novartis AG, and Novartis AG, and ii) the Separation and Distribution Agreement among RNA, Novartis AG, and Bryce Therapeutics, Inc., a wholly owned subsidiary of Avidity which has since changed its name to Atrium Therapeutics, Inc. (“SpinCo”).

The Distribution was approved by Avidity Biosciences, Inc. shareholders and became effective on February 27, 2026. The “RNA” symbol was recycled for the listing of the Common Shares of Atrium Therapeutics, Inc. Adjusted Avidity Biosciences, Inc. options were adjusted on February 27, 2026 (See OCC Information Memo #58435) The new deliverable became 1) 100 Avidity Biosciences, Inc. (RNAS) Common Shares and 2) 10 Atrium Therapeutics, Inc. (RNA) Common Shares.

**The merger was approved and subsequently consummated before the open on February 27, 2026.** As a result, each existing RNAS Common Share will be converted into the right to receive \$72.00 net cash per share.

RNA1 options will be further adjusted to reflect the cash merger consideration as described below.

**Contract Adjustment**

**Date:** February 27, 2026

**Option Symbol:** RNA1 remains RNA1

**Strike Divisor:** 1

**Contracts Multiplier:** 1

**New Multiplier:** 100 (e.g., a premium of 1.50 yields \$150; a strike of 45 yields \$4,500.00)

**New Deliverable**

**Per Contract:** 1) 10 Atrium Therapeutics, Inc. (RNA) Common Shares  
2) \$7,200.00 Cash (\$72.00 x 100)

**CUSIP:** RNA: 04965N104

**Pricing**

The underlying price for RNA1 will be determined as follows:

$$\text{RNA1} = 0.10 (\text{RNA}) + 72.00$$

**Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and futures and the nature of any adjustment is made by OCC pursuant to Chapter 28 (XXVIII) of OCC's Rules. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

**ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.**

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).